In a study of hypogonadal men older than 65, the treatment did not increase the prevalence of thrombotic events.
Patients experienced significant improvements in symptoms and quality of life parameters.
Hypogonadism was present in 42.8% of subjects, yet TRT was used by only 3.9%.
Researchers also found that clinicians prescribed testosterone replacement therapy to men of reproductive age despite the risks.
Lower testosterone levels linked to decreased sexual activity and desire, but not to fewer erections.
In this study, over half the men referred for borderline testosterone levels had depression.
Among men younger than age 40, a total testosterone level of less than 400 ng/dL was linked with hypogonadal symptoms.
New data from two studies indicate that testosterone therapy is not associated with cardiovascular risks, which challenges recent FDA decisions.
Three doses of testosterone nasal gel may help normalize testosterone levels in men with hypogonadism.
Prescription testosterone product labels must now include warnings about the possible increased risk of heart attacks and strokes, says FDA.
Long-term testosterone therapy in hypogonadal men is safe, an observational study suggests. New cases of prostate cancer were lower than expected.
Investigators evaluated the correlation between hypogonadal symptoms and serum testosterone levels using ADAM questionnaire.
Increased likelihood of testing in men with comorbidity associated with hypogonadism.
Testosterone replacement therapy (TRT) does not increase cardiovascular disease (CVD) risk.
Greater PSA increases seen in older men and those with lower baseline testosterone.
Testosterone replacement therapy (TRT) may lower hemoglobin levels and improve lipid profile in diabetic men with androgen deficiency.
Low total testosterone was associated with increased odds of greater carotid intima-media thickness and odds of endothelial dysfunction.
Testosterone replacement therapy (TRT) may promote prostate cancer tumor growth.
Low testosterone may increase cardiovascular (CV) risk in middle-aged men with type 2 diabetes.
Testosterone therapy for men who produce little to no hormones does not increase heart attack risk.
Joint committee also calls for drug makers to run heart-risk tests on popular 'Low T' products.
Expert panel to decide whether prescribing information on testosterone drugs should be changed.
Chemicals found in many household products may reduce androgen levels in both sexes.
Obesity can lead to a deterioration of erectile function in young men.
Finding runs counter to some prior reports; much larger trials are needed, experts say.
In a study, 74% of men treated with Vogelxo achieved normal testosterone levels within 90 days.
Researchers report findings from a study of 942 hypogonadal men treated at 3 German centers.
The product is self-administered via a nasal applicator.
Study also shows a 6-fold higher rate of hypogonadism compared with the general population.
For men with T2DM and low testosterone, tx also doesn't improve visceral adiposity.
Drop in testosterone levels in patients on active surveillance may predict need for treatment.
Weight, frequent exercise, and adult-onset diabetes are among the risk factors for hypogonadism.
Patients in the second lowest quintile of testosterone level had a 53% increased death risk compared with those in the highest quintile.
Parenteral testosterone undecanoate over 5 years found to decrease waist circumference and improve components of metabolic syndrome.
Elevated serum estradiol is associated with increased libido in men receiving TST.
In men aged 44 years or less, total testosterone levels drop off significantly after 9 AM, study shows.
Risk is higher in younger men with pre-existing heart disease and in older men.
Agency pointed to recent studies citing possible heightened heart risk tied to the treatments.
Preoperative levels below 300 ng/dL are associated with an increased risk of positive surgical margins and seminal vesicle invasion.
In fact, a study showed that testosterone replacement is associated with a decreased risk of cancer-specific and overall mortality.
New findings could help explain why women generally respond immunologically to vaccines more strongly than men.
Long-term treatment led to a decrease in Crohn's Disease Activity Index and high-sensitivity C-reactive protein.
Australian researchers report that testosterone levels may predict mortality risk in older men.
About 30 percent of men experience an AUA symptoms index improvement of 3 or more points.
Midrange levels of total testosterone and dihydrotestosterone are associated with decreased all-cause mortality.
The drug combination was associated with significantly improved erectile function and partner satisfaction in men who did not respond to testosterone alone.
In a study, it was associated with a 29% increased risk of death and/or heart attack or stroke.
Men with low testosterone levels may be at slightly increased risk of developing or dying from cardiovascular disease.
Improvements observed in urinary symptoms and bone mineral density.
The drug increases testosterone levels by lower serum estradiol levels.
Men with a body mass index of 30 kg/m2 or higher had a 39.3% prevalence of low testosterone, study finds.
Significant declines in International Prostate Symptom Score observed, regardless of whether or not men lost weight or used a phosphodiesterase-5 inhibitor.
Researchers observed significant improvements in lipid parameters, blood glucose, and blood pressure.
A new clinical review on cardiovascular disease and testosterone published between 1970 and 2013 has turned up mixed findings.
Prediabetes increases the risk of testosterone deficiency nearly twofold.
Testosterone levels in the lowest versus the highest quintile are associated with a 15-fold increased risk of metabolic syndrome, study finds.
Low bioavailable testosterone significantly increased the risk in men aged 80 and older.
Review of the literature conducted to assess low testosterone link to cardiovascular disease/mortality.
Desmopressin appears to reduce nocturia and other LUTS while also significantly increasing testosterone levels in late-onset hypogonadism.
Study demonstrates that men experience steady weight loss and decrease in waist circumference.
New findings could improve the evaluation and management of men with hypogonadism.
Prior use of AAS is common among young men seeking treatment for symptomatic hypogonadism.
Findings from a mouse study implicate increased nitric oxide production.
In a study, 55% of male hemodialysis patients had low testosterone.
Lower urinary tract symptoms actually improved in many men, with minimal change in PSA level.
A new study looking at men with low testosterone levels has found that testosterone therapy helps improve pain perception and quality of life.
Hypogonadal men younger than 50 years were more than 10 times as likely as men older than 50 to have prior exposure to anabolic androgenic steroids.
PSA levels below 0.65 ng/mL provide the best sensitivity and specificity (65.2% and 55.5%, respectively) for predicting severe hypogonadism.
After radical prostatectomy, men who received testosterone therapy for hypogonadism had a lower rate of biochemical recurrence than nonhypogonadal men.
Study also reveals very low use of testosterone replacement therapy among men in the United States
BMI and waist circumference declined in hypogonadal men treated with parenteral testosterone undecanoate.
Researchers studied 850 testosterone-deficient men who received 1,000 mg parenteral testosterone undecanoate six weeks after baseline and then every 12 weeks for up to five years.
Hypogonadal men aged 65 years and older experience significant benefit from TRT over 12 months.
California researchers have found that low testosterone levels occur five times more often among men taking long-acting opioids.
In men taking daily opioids, duration of action, but not dose, affects risk of hypogonadism
Researchers reviewed clinical trial and postmarketing data.
Adding testosterone therapy to sildenafil is not more effective in treating erectile dysfunction (ED) than sildenafil alone,
Sildenafil plus testosterone not superior for men with erectile dysfunction, low testosterone.
Researchers predict about 1.3 million new cases of cardiovascular disease related to low testosterone over a 20-year period.
How concerned are you that placing hypogonadal men on testosterone replacement therapy might promote development of prostate cancer (PCa) or progression of undiagnosed PCa?
Many physicians remain wary about starting testosterone replacement therapy (TRT) in hypogonadal men in large part out of concern that it could cause progression of undiagnosed prostate cancer (PCa) or promote PCa development.
Long-term treatment found not to increase the incidence of prostate cancer.
Finding was based on a study of 1,365 men with symptomatic androgen deficiency.
Measures that led to weight loss found to raise levels significantly in overweight, prediabetic men.
Treatment is associated with weight loss and improvements in components of metabolic syndrome.
Study implicates factors other than aging, including weight gain, smoking cessation, depression and cardiovascular disease.
One case of cancer diagnosed per 212 years of testosterone replacement therapy
The FDA has approved two lower-dose formulations for Androderm, a once-daily transdermal patch for men with low testosterone.
ORLANDO, Fla.—Testosterone supplementation in elderly men with borderline low testosterone levels may not improve erectile dysfunction (ED) compared with placebo, new findings suggest.
The ratio of the second and fourth finger lengths (2D/4D ratio) may predict which men have testosterone deficiency, researchers reported.
WASHINGTON, D.C.—The FDA has approved the first and only testosterone therapy applied to the underarm.
The FDA has approved Abbott's AndroGel 1.62%, a testosterone gel that restores levels of the hormone in hypogonadal men with half the volume of gel at the starting dose than delivered in AndroGel 1%.
Low testosterone increases fat mass and visceral obesity, which is associated with insulin resistance.
A history of prostate cancer has generally been a contraindication for testosterone therapy, but the clinical model may be changing.
VIENNA—Testosterone replacement therapy benefits hypogonadal men without adversely affecting prostate safety, according to the largest international trial of hypogonadal men receiving the treatment.
Salivary testosterone (Sal-T) can be used to diagnose androgen deficiency reliably in men with end-stage renal disease (ESRD), according to a Brazilian study.
Dihydrotestosterone (DHT) treatment over two years does not halt prostate growth, according to study findings published in the Annals of Internal Medicine (2010;153:621-632).
A study of 930 men with coronary heart disease (CHD) showed that those who had testosterone deficiency were at increased risk of death.
The FDA has approved a testosterone replacement therapy gel, a colorless and odorless preparation applied with one finger to the front and inner thighs.
Endocrinologist William Rosner, MD, Professor of Medicine at Columbia University in New York, explains to Renal & Urology News what impending testosterone-testing standardization—and the current lack of it—means to urology practice and research.
Statin therapy may induce primary hypogonadism and should be considered a possible confounding factor when evaluating testosterone levels in patients with erectile dysfunction (ED), according to Italian researchers.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)